FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to psychiatry, and can be used to monitor the condition of patients with endogenous psychoses, as well as to assess the severity of the mental state. A method for assessing the mental state of patients with endogenous mental disorders includes clinical observation and psychometric examination. Additionally, a complex assessment of the state of the immune system, in this case, the enzymatic activity of leukocyte elastase (LE), functional activity α1-Proteinase inhibitor (α1-PI) and the level of autoantibodies to neuroantigens - the main protein of myelin (MPM) and the protein S100B. Evaluation of the mental state of patients is carried out by comparing the degree of deviation of the determined immunological parameters of blood serum from the similar indicators of serum samples of healthy individuals. Group of inventions also refers to assessing the state of the immune system of patients with endogenous psychiatric disorders. Range of activity of leukocyte elastase (LE) - (201-250) nmol/min × ml is characterized as a slight increase, range - (251-300) nmol/min × ml - a moderate increase, and an increase in activity (LE) of more than 300 nmol/min × ml - marked increase in normal PE activity in human serum - (150-200) nmol/min × ml. Reduced or normal activity α1-proteinase inhibitor (α1-PI) with increased LE activity testifies to insufficiency of antiproteolytic activity of blood serum under normal activity α1-PI - (28-32) IE/ml; and an increase in the level of autoantibodies (aAT) to the main myelin protein (MPM) and protein S100B, at a rate of (0.6-0.9) units. opt. pl. characterizes the presence of an autoimmune component of the pathological process in the brain.
EFFECT: use of this group of inventions makes it possible to carry out a comprehensive assessment of the mental state of patients with endogenous mental disorders, taking into account the pathological process in the brain at a certain time interval of the development of the disease, reflecting the degree of activity (severity) of the psychotic state.
3 cl, 2 ex, 1 tbl, 2 dwg
Title | Year | Author | Number |
---|---|---|---|
METHOD OF DETERMINING THE NECESSITY OF USING PSYCHO PHARMACOTHERAPY AMONG THE PATIENTS WITH DISORDERS OF AUTIST SPECTRUM AT THE MOMENT OF THEIR EXAMINATION | 2017 |
|
RU2643760C1 |
DIAGNOSTIC TECHNIQUE FOR ASTHENIC SYNDROME IN SCHIZOPHRENIC PATIENTS | 2019 |
|
RU2709105C1 |
METHOD FOR PREDICTION OF FUNCTIONAL RECOVERY OF PATIENTS WITH ISCHEMIC STROKE | 2018 |
|
RU2694541C1 |
METHOD FOR PREDICTION OF THE PROBABILITY OF AN UNFAVORABLE OUTCOME IN RELATION TO THE SOCIAL POSTPSYCHOTIC FUNCTIONING OF THE PATIENTS WITH ENDOGENOUS PSYCHIC DISEASES | 2018 |
|
RU2706216C1 |
METHOD FOR PREDICTION OF CLINICAL COURSE OF SCHIZOPHRENIA IN MEN WITH PAROXYSMAL ENDOGENOUS PSYCHOSES MANIFESTING AT AGE FROM 18 TO 25 YEARS | 2018 |
|
RU2685549C1 |
METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENT OF PATIENTS WITH SCHIZOPHRENIA | 2021 |
|
RU2775440C1 |
METHOD OF LABORATORY DETECTION OF CONSEQUENCES OF PERINATAL CENTRAL NERVOUS SYSTEM AFFECTIONS AND SEVERITY DETERMINATION IN CHILDREN | 2010 |
|
RU2425371C1 |
PREDICTION METHOD OF THERAPY EFFECTIVENESS IN PATIENTS WITH PAROXYSMAL SCHIZOPHRENIA | 2016 |
|
RU2621266C1 |
METHOD FOR PREDICTING EFFECTIVENESS OF OLANZAPINE ATYPICAL ANTIPSYCHOTIC DRUG THERAPY IN SCHIZOPHRENIA PATIENTS | 2017 |
|
RU2680529C1 |
LABORATORY DIAGNOSTIC TECHNIQUE FOR SCHIZOTYPAL DISORDER | 2014 |
|
RU2569741C1 |
Authors
Dates
2018-03-28—Published
2016-12-15—Filed